Publications by authors named "Andrew D Goodman"

Claim this Profile
D
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
John R Corboy, Robert J Fox, Gary Cutter, Eric Engebretson, Aaron Miller, Andrew D Goodman

Mult Scler· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Dejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, Andrew D Goodman, Malcolm Gottesman

J Neurol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose vitamin D supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial.
Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo, Andrew D Goodman

EClinicalMedicine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Corey C Ford, Jeffrey A Cohen, Andrew D Goodman, John W Lindsey, Robert P Lisak

Mult Scler· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Jeffrey A Cohen, Michelle H Cameron, Myla D Goldman, Andrew D Goodman, Aaron E Miller

Mult Scler· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Dejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, Andrew D Goodman, Patricia K Coyle

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Robert J Fox, Paola Raska, Christian Barro, Matthew Karafa, Victoria Konig, Andrew D Goodman

Mult Scler· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
Robert A Bermel, Janel K Fedler, Peter Kaiser, Cindy Novalis, Jeff Schneebaum, Andrew D Goodman

Mult Scler· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials.
Timothy Coetzee, Mad Price Ball, Marc Boutin, Abby Bronson, David T Dexter, Andrew D Goodman

J Particip Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.
Seth N Levin, Shruthi Venkatesh, Katie E Nelson, Yi Li, Ines Aguerre, Andrew D Goodman

Ann Clin Transl Neurol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data Sharing Goals for Nonprofit Funders of Clinical Trials.
Timothy Coetzee, Mad Price Ball, Marc Boutin, Abby Bronson, David T Dexter, Andrew D Goodman

J Particip Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
Robert T Naismith, Robert A Bermel, Christopher S Coffey, Andrew D Goodman, Janel Fedler

Neurology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings.
Nidhiben Anadani, Megan Hyland, Roberto Alejandro Cruz, Robert Lisak, Kathleen Costello, Andrew D Goodman

Neurol Neuroimmunol Neuroinflamm· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
Andrew D Goodman, Janel K Fedler, Jon Yankey, Elizabeth A Klingner, Dixie J Ecklund

Ann Clin Transl Neurol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siponimod in the treatment of multiple sclerosis.
Andrew D Goodman, Nidhiben Anadani, Lee Gerwitz

Expert Opin Investig Drugs· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of telemedicine versus in-person visits for persons with multiple sclerosis: A randomized crossover study of feasibility, cost, and satisfaction.
Jessica F Robb, Megan H Hyland, Andrew D Goodman

Mult Scler Relat Disord· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew D Goodman

CNS Drugs· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel computer-based testing shows multi-domain cognitive dysfunction in patients with multiple sclerosis.
Andrew D Smith, Charles Duffy, Andrew D Goodman

Mult Scler J Exp Transl Clin· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibudilast for the treatment of multiple sclerosis.
Andrew D Goodman, Tirisham Gyang, Andrew D Smith

Expert Opin Investig Drugs· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
Robert Zivadinov, Diane L Cookfair, Lauren Krupp, Aaron E Miller, Neil Lava, Andrew D Goodman

BMC Neurol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fingolimod-associated PML in a patient with prior immunosuppression.
Tirisham V Gyang, Johanna Hamel, Andrew D Goodman, Robert A Gross, Lawrence Samkoff

Neurology· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interrelations between spiritual well-being, pain interference and depressive symptoms in patients with multiple sclerosis.
Sheri A Nsamenang, Jameson K Hirsch, Raluca Topciu, Andrew D Goodman, Paul R Duberstein

J Behav Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: The interrelations between spiritual well-being, pain interference and depressive symptoms in patients with multiple sclerosis.
Sheri A Nsamenang, Jameson K Hirsch, Raluca Topciu, Andrew D Goodman, Paul R Duberstein

J Behav Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Angela Applebee, Andrew D Goodman, Angeli S Mayadev, Francois Bethoux, Myla D Goldman

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Andrew D Goodman, Francois Bethoux, Theodore R Brown, Randall T Schapiro, Ron Cohen

Mult Scler· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis